Drug Profile
Research programme: crotamine - Celtic Biotech Iowa
Alternative Names: CB-5Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Instituto Butanan
- Developer Celtic Biotech Iowa
- Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lung cancer
Most Recent Events
- 29 Aug 2023 Crotamine is still in preclinical development for Lung cancer (Diagnosis) in USA (Celtic Biotech pipeline, August 2023)
- 20 Jun 2023 Crotamine is still in preclinical development for Lung cancer (Diagnosis) in USA (Celtic Biotech pipeline, June 2023)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Lung-cancer(Diagnosis) in USA (Parenteral)